{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:46Z","timestamp":1793982286503,"version":"4.8.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41409-026-03013-w","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:57:50Z","timestamp":1787014670000},"page":"1566-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-7969","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Khvedelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-6900","authenticated-orcid":false,"given":"Maud","family":"Ngoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-2450","authenticated-orcid":false,"given":"Maria","family":"Gomes da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4655-6488","authenticated-orcid":false,"given":"Gilles","family":"Crochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3555-2887","authenticated-orcid":false,"given":"Jaroslaw","family":"Dybko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Zeberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Martin Garcia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-2833","authenticated-orcid":false,"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-6333","authenticated-orcid":false,"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"3013_CR1","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555\u201367.","DOI":"10.1200\/JCO.21.02370"},{"key":"3013_CR2","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42:1146\u201357.","journal-title":"J Clin Oncol"},{"key":"3013_CR3","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","volume":"6","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6:3606\u201310.","journal-title":"Blood Adv"},{"key":"3013_CR4","doi-asserted-by":"crossref","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41:2594\u2013606.","DOI":"10.1200\/JCO.22.01797"},{"key":"3013_CR5","doi-asserted-by":"crossref","unstructured":"Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024;109:3745\u201350.","DOI":"10.3324\/haematol.2023.284786"},{"key":"3013_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.87","volume":"8","author":"MA O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. Hemasphere. 2024;8:e87.","journal-title":"Hemasphere"},{"key":"3013_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024;143:673\u201384.","journal-title":"Blood"},{"key":"3013_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/bloodadvances.2025018137","volume":"10","author":"EP Darnell","year":"2026","unstructured":"Darnell EP, Gallagher KME, Kanska J, Scarf\u00f2 I, Balderrama-Gutierrez G, Berger TR, et al. Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026;10:1023\u201334.","journal-title":"Blood Adv"},{"key":"3013_CR9","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O\u2019Brien M, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6:5774\u201385.","journal-title":"Blood Adv"},{"key":"3013_CR10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650\u201360.","journal-title":"Blood"},{"key":"3013_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A, Rejeski K, Kwon M, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42:205\u201317.","journal-title":"J Clin Oncol"},{"key":"3013_CR12","doi-asserted-by":"crossref","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378.","DOI":"10.1038\/s41591-024-03084-6"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03013-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03013-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03013-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:41Z","timestamp":1793978861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03013-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3013"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03013-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G Iacoboni\u2014Consulting: Autolus, Bristol-Myers Squibb, Kite\/Gilead, Janssen, Miltenyi, AbbVie, MSD, Regeneron. Honoraria: AbbVie, AstraZeneca, BMS, Kite\/Gilead, Miltenyi, Sobi, Roche, Lilly. Travel support: AbbVie, AstraZeneca, Kite\/Gilead, Miltenyi, Roche. P Barba\u2014Consultancy: Jazz Pharmaceuticals, Nektar, Pierre Fabre, Miltenyi Biomed, Novartis, Pfizer, BMS\/Celgene\u2014Support for attending meetings and\/or travel: Kite\/Gilead, Novartis, Pfizer\u2014Advisory Board: Allogene, BMS\/Celgene, Incyte, Pierre Fabre, Amgen, Kite\/Gilead, Novartis, Miltenyi Biomed, Autolus, Nektar, Pfizer. P Corradini\u2014Consulting: Bristol-Myeres Squibb, Kite\/Gilead, Roche, BeOne, Janssen. Honoraria: Bristol-Myeres Squibb, Kite\/Gilead, Roche, BeOne, Lilly, Sobi, Novartis. Travel support: AbbVie, AstraZeneca, Kite\/Gilead, Roche, Novartis, BeONE. P Sesques: Honoraria from Novartis, Kite\/Gilead, Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Roche, and Chugai. M Gomes da Silva\u2014Research grants: AstraZeneca; Consulting: Roche, Janssen, Lilly, Decera Medica Education; Travel support: Kite\/Gilead, Janssen, AbbVie, Roche. G Crochet\u2014Consulting: Roche, Kite\/Gilead, AbbVie, Incyte, BMS, Sobi, Janssen. Honoraria: Roche, Kite\/Gilead, AbbVie, Incyte, BMS, Sobi, Janssen. Travel support: Kite\/Gilead, Roche, Sobi A, Mart\u00edn Garc\u00eda-Sancho. Honoraria: AbbVie, AstraZeneca, BeOne, BMS, Gilead\/Kite, Ideogen, Incyte, Janssen, Kyowa Kirin, Lilly, Regeneron, Roche, Sobi, Takeda. Consulting fees: AbbVie, AstraZeneca, BeOne, BMS, Genmab, Gilead\/Kite, GSK, Janssen, Lilly, MSD, Regeneron, Roche, Sobi. R Sanderson\u2014Honoraria: Kite\/Gilead, Novartis. Travel support: Kite\/Gilead, AstraZeneca. Medical education: Kite\/Gilead, AbbVie. Adboard: Kite\/Gilead, Autolus. A Sureda: Honoraria: Takeda, BMS\/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals, Pierre Fabre; Consultancy: Takeda, BMS\/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie; Speaker\u2019s Bureau: Takeda; Research Support: Takeda; Non-profit organizations: Presidency of the EBMT. P. Dreger: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. He is the current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). A Bazarbachi: Speaker bureau or advisory board: Novartis, Roche, Sanofi, Jazz, Adienne, Astellas, Takeda, Hikma, Janssen, MSD, AbbVie, Pfizer, and Amgen. Research support: Novartis, Roche, Takeda, Janssen, Astellas, Biologix, Pfizer, and Amgen.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}